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Infections by methicillin-resistant Staphylococcus aureus (MRSA) play an increasing role
in the postoperative course. Although wound infections after cardiac surgery are rare,
the outcome is limited by the prolonged treatment with high mortality. Not only surgical
debridement is crucial, but also antibiotic support. Next to vancomycin and linezolid, dapto-
mycin gains increasing importance. Although clinical evidence is limited, daptomycin has
immunomodulatory properties, resulting in the suppression of cytokine expression after
host immune response stimulation by MRSA. Experimental studies showed an improved
efficacy of daptomycin in combination with administration of vitamin E before infecting
wounds by MRSA.
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Infections with methicillin-resistant Staphylococcus aureus
(MRSA) are an increasing problem worldwide and although
MRSA is less prevalent in northern Europe, its appearance in hos-
pitals and especially in intensive care unit is highly problematic
(1, 2). MRSA infections after cardiac surgery are responsible for
high in-hospital mortality (3). In general, infections after heart
surgery may be systemic infections but also quite often related
to the wounds (Figure 1). Postoperative pneumonia is mainly
ventilator associated and the risk is increased with prolonged dura-
tion of postoperative mechanical ventilation (4, 5). Bloodstream
infections after open-heart surgeries are very rare (6, 7). These
infections are probably related to transfusion and especially to red
blood cell units that are older than 14 days (6). Contamination of
the cardiopulmonary circuit and its compounds seems to be less
important. Although in the study of Hamers and colleagues pos-
itive cultures from cardiopulmonary bypasses were not a rarity,
they did not register increased risk of postoperative infections (8).
The data regarding postoperative endocarditis are comparable to
bacteriemia; sporadic cases have been reported. Wound infections
after open-heart surgery are of the most serious complications.
Deep wound infections are post-sternotomy associated and may
involve the mediastinal area and the sternal bone (Figure 2). The
incidence of postoperative mediastinal wound infection is mostly
around 2% but may rise up to 5% (9–13). The “mechanisms” of
wound infection are (i) peri-operative contamination, (ii) spread
from concomitant infection, or (iii) associated with comorbidi-
ties (e.g., chronic obstructive lung disease). S. aureus mediastinal
infections are mainly caused by peri-operative contamination
(12). Due to increased postoperative mortality of around 20%,
deep wound infections and mediastinitis remain a very serious
complication after cardiac surgery (12).
In case of MRSA-related post-sternotomy infection, even long-
term survival was significantly reduced (14, 15). In contrast to
these findings, in a recently published study of 4,722 patients who
underwent coronary artery bypass grafting, Colombier et al. did
not find that long-term survival was influenced by MRSA infec-
tions (15). Nevertheless, they reported in-hospital mortality three
times higher than in patients without deep wound infections (16).
However, early and aggressive treatment is crucial. Despite pre-
venting strategies and surgical treatment, including removal of
foreign material and extended wound debridement, antibiotics are
an essential part of the therapy. In case of MRSA, antimicrobial
therapy is limited due to the resistance to many antibiotics, includ-
ing third-generation-cephalosporins, macrolides, and quinolones.
The intravenous administration of vancomycin is the primary
therapeutic option for MRSA infections (17). Vancomycin is a gly-
copeptide inhibiting the synthesis of the bacterial cell wall. Carrier
et al. reported the implementation of many strategies to control
contamination after an outbreak of MRSA mediastinal infections
(18). They reduced the incidence of MRSA infection and medias-
tinitis after cardiac surgery among patients with MRSA infection
or nasal carriers of MRSA, giving prophylactic vancomycin along
with preventing isolation and nasal application of mupirocin. In
a decision analysis model to estimate surgical site infections in
cardiothoracic surgery, Miller and colleagues found the risk of
surgical site MRSA infections after prophylactic application of
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FIGURE 2 |Types and interactions of post-sternotomy wound
infections.
vancomycin and therefore they suggest routine prophylaxis with
vancomycin (19). Walsh et al. gave in their MRSA intervention pro-
gram vancomycin prophylaxis for identified MRSA carriers along
with intranasal mupirocin application to all patients regardless
of colonization status (20). Their strategy resulted in a near-
complete elimination of MRSA wound infections after cardiac
surgery. Unselected, general prophylaxis with vancomycin may be
problematic. In this context, Bull et al. found in a large analy-
sis of 22,549 procedures, including aortocoronary bypass grafting
and orthopedic procedures, an increased risk of wound infections
caused by methicillin-sensitive S. aureus strains (21). However,
also development of intermediate glycopeptide-resistant strains
has been reported (22). Linezolid is an alternative to vancomycin
and is, in contrast to vancomycin, completely bioactive after oral
administration. The oral application is associated with increased
patient comfort especially in patients with long-lasting treatment
and in cases treated in the out-patient department. The efficacy
of both treatments, vancomycin and linezolid, is comparable (23,
24). Although both agents were well tolerated, thrombocytope-
nia, anemia, diarrhea, and nausea were more often presented in
patients treated by linezolid (25). The biggest problem in soft-
tissue infections is the tissue penetration of the antimicrobial
drugs. Distribution of vancomycin into soft tissue is variable (26).
Concentrations of linezolid in soft tissue are similar or higher than
plasma levels, although some variability exists.
Daptomycin, a novel cyclic lipopeptide antibiotic, is effective in
soft-tissue infections, in hospitalized patients, and in community-
acquired infections (27). Penetration of daptomycin into soft
tissue is good, with reported concentrations of more than 70%
of the plasma level within 2 h of administration and maintenance
of these levels for 12 h (28). Early experimental studies demon-
strated efficacy of daptomycin also in a pneumonia model, but
the effect was no superior to vancomycin treatment (29). Because
daptomycin had failed to meet the statistical endpoint in a phase
3 trial for the treatment of community-acquired pneumonia, this
antimicrobial is not indicated for use in the treatment of pneu-
monia (30, 31). Daptomycin has shown to be effective even for
treatment of MRSA wound infections in cardiac surgery (32). The
basic characteristics of vancomycin, linezolid, and daptomycin are
summarized in Table 1. The overall clinical success rates of dapto-
mycin therapy were reported above 90% (33). Diabetes and severe
renal impairment along with andocarditis and bacteriemia were
associated with higher rates of clinical failure (33). Also regarding
surgical wound infections caused by MRSA, the success rates were
comparable high, regardless of the depth of the infection (34).
In wound infections, the daily dosage of daptomycin is usually
4 mg/min. However, in multicenter, retrospective studies high-
dose daptomycin (daily more than 8 mg/kg) were effective in com-
plicating infections, including wound infections, with low adverse
events (35, 36). Daptomycin has bactericidal activity caused by the
calcium-dependent release of potassium and membrane potential
dissipation. This mechanism is ultimately leading to cytoplasmic
membrane disruption and cell death (37). Pogliano and colleagues
found that the membrane defects occur rapidly within 15 min (38).
They observed also that daptomycin inserts preferentially in the
leading edges of the septal and forespore membranes, also induc-
ing changes in the membrane structure. Furthermore, they found
relocalization of the peptidoglycan biogenesis apparatus. Along
with the reorganization of the membranes, daptomycin is respon-
sible for the cell shape and membrane alterations. Therefore,
daptomycin is likely to be directly responsible for mislocaliza-
tion of essential cell division proteins (38). Recently, Berti and
colleagues found enhanced activity of daptomycin against MRSA
in the presence of β-lactam antibiotics (39). Although the exact
mechanism is not clear, this effect was related to the interfer-
ence of the β-lactam antibiotics (in subinhibitory concentrations)
with the penicillin-binding protein 1. Furthermore, daptomycin
was more effective in inhibiting MRSA in biofilm than linezolid
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Table 1 | Basic characteristics of the MRSA active antibiotics
vancomycin, linezolid, and daptomycin.
Vancomycin Linezolid Daptomycin
Chemistry Glycopeptide Oxazolidinone Cyclic lipopeptide
Activity Bactericide Bactericide Bactericide
Target Cell wall Protein synthesis Cell membrane
Application i.v. i.v. and per oral i.v.
Daily dosagea 2×1,000 mg (or
4×500 mg)
2×600 mg 1×4 mg/kg
aAccording to the recommendations of producer; i.v., intravenous.
and vancomycin (40). After surgery and especially after cardiac
surgery with implants and osteosynthetic material, biofilm forma-
tion by antibiotics in subminimal inhibitory concentrations may
play a significant role (41). Recently, the efficacy of daptomycin on
MRSA biofilms could be increased by synergetic interaction with
the antimiocrobial cationic peptide nisin (42).
Interestingly, S. aureus is stimulating the production of inflam-
matory cytokines (43). Antibiotics may have immunomodulatory
properties during an infection. In an experimental in vitro study
on peripheral blood mononuclear cells, Pichereau et al. found
that many different antibiotics tended to reduce the production
of cytokines after toxin exposure (43). Some of these drugs were
vancomycin, linezolid, daptomycin, clindamycin, and tigecycline.
The inhibiting effects of daptomycin at clinical serum peak con-
centrations (cmax) on the production of interleukin-1β (IL-1β),
IL-6, IL-8, interferon-γ, and tumor necrosis factor alpha (TNF-
α) were variable. The suppression of cytokine production was by
most antibiotics concentration-dependent but not in the case of
daptomycin (and vancomycin). Thallinger and colleagues, in an
experimental model of human endotoxemia, found no effect of
daptomycin on levels of IL-1β, IL-6, and TNF-α probably due to
a high affinity of daptomycin to bacterial cytoplasmic membrane
and its low potential to penetrate into human cells (44).
A new very interesting aspect of immunomodulation of dapto-
mycin is related to immune enhancement. Vitamin E is an immune
enhancer. Salinthone and colleagues found immunomodulatory
properties of vitamin E also in human peripheral mononuclear
cells due to alteration of cytokine production (IL-2, IL-8, and
IL-17) in part by stimulating production of cyclic adenosine
monophosphate (cAMP) (45). In an animal model, administra-
tion of vitamin E before infecting wounds by MRSA improved the
efficacy of daptomycin (46). Furthermore, Pierpaoli et al. found
that if animals were treated with vitamin E before the wounds
were infected with MRSA, the animals showed significantly
increased CD49b+ cells after the application of daptomycin while
daptomycin alone did not change leukocyte populations (47).
Unfortunately, there is not enough clinical data available
regarding immunomodulation in patients, but clinical studies
demonstrated that “clinical failure in daptomycin-treated skin and
soft-tissue infections is associated with severity of infection,” e.g.,
sepsis, intensive care unit stay, and renal insufficiency (27). These
findings support the hypothesis that reduced immune responses
correlate directly with MRSA vulnerability. The result is a vicious
cycle compromising the immune response ability of the patient
and in turn leading to a further deterioration of clinical condi-
tion. However, it is very interesting to think about possibilities
to break this vicious cycle. Of course, antibiotics “kill” bacteria
directly but could, for example, the application of vitamin E sup-
port the efficacy of daptomycin in humans? And if yes, when
should the application of vitamin E, take place, simultaneously
with daptomycin or before the antibiotic treatment? In the previ-
ously mentioned experimental studies, animals were treated with
vitamin E before the wounds were infected by MRSA. Should we
therefore perhaps pre-treat all patients with vitamin E or at least
patients at risk of MRSA colonization before any surgery? At the
moment, we do not have answers to these questions but these
questions may stimulate further clinical research on this topic.
The results from experimental studies are very encouraging.
CONCLUDING REMARKS
Infections after open-heart surgery are complications seriously
endangering survival. Wounds infected by MRSA are extremely
difficult to manage due to their resistance to many antibiotics.
Vancomycin is the first-choice antibiotic but only available intra-
venously. Linezolid is also available per oral and has compa-
rable effects. Daptomycin has good tissue penetration and is
more effective in biofilm. The latter effect may be important
in treatment after open-heart surgery due to surgical implants.
Although clinical evidence is limited, it suggests that dapto-
mycin causes immunomodulation suppressing dose-independent
cytokine production after stimulation by MRSA. In experimental
studies, immune enhancers (e.g., vitamin E) increased efficacy of
daptomycin.
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